NASDAQ · OKYO
OKYO Pharma Limited
$1.50+$0.01 (+0.67%)
OKYO Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 53.13% below the high.
Loading market information…
NASDAQ · VBIO · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Valion Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.09% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Valion Bio, Inc.’s next earnings report is currently expected on Nov 13, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Valion Bio, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Mar 28, 2025 |
| -$2.65+97.77% vs estimate |
| $180.00K-86.47% vs estimate |
| Q4 2025 | Mar 20, 2025 | -$2.64+96.89% vs estimate | $0.00-100.0% vs estimate |
|---|
| Q3 2025 | Nov 15, 2024 | -$3.93+96.7% vs estimate | $126.00K-83.85% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.50+$0.01 (+0.67%)
OKYO Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 53.13% below the high.
$0.15-$0.01 (-8.96%)
Vinergy Capital Inc.’s quoted price sits in the upper half of its reported 52-week range, 48.39% below the high.
$0.16-$0.03 (-15.36%)
TPCO Holding Corp.’s quoted price sits in the lower half of its reported 52-week range, 83.81% below the high.
€2.94-€0.11 (-3.61%)
Biofrontera AG’s quoted price sits in the lower half of its reported 52-week range, 43.24% below the high.
$2.74-$0.01 (-0.27%)
Organicell Regenerative Medicine, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.86% below the high.
$0.01-$0.04 (-76.0%)
Antisense Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 84.0% below the high.
$0.98$0.00 (0.0%)
American Hemp Ventures, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.82% below the high.
$3.21-$0.10 (-3.02%)
Kadimastem Ltd’s quoted price sits in the lower half of its reported 52-week range, 64.61% below the high.
